|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||
![]() |
|||||||||||||||||||||||||||||||||||||||||||
(Return
to page 17)
|
By William Palumbo, MS, RD, CDN | ||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||
| Drug
Interactions:
Cytochrome P450 Effect: CYP3A3/4 enzyme substrate Increased Effect/Toxicity: Clofibrate, fenofibrate, gemfibrozil, and niacin may increase the risk of myopathy and rhabddommyolysis. Imidazole antifungals (itraconazole, ketoconazole, P-glycoprotein inhibitors )may increase pravastatin concentrations. Decreased effect: Concurrent administration of cholestyramine or colestipol can decrease pravastatin absorption.
|
|||||||||||||||||||||||||||||||||||||||||||
| No part of this newsletter may be reproduced in any form without permission from the publisher. Copyright 2003 HIV ReSources, Inc. Email: subscriptions@hivresources.com | |||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
PO Box 39385 Fort Lauderdale, FL 33339-9385 USA |
|
Any use of the information presented herein is done strictly at your own risk. No responsibility is implied or intended on the part of HIV ReSources Inc, the editor, or the publisher. Information on this site should not be construed as an endorsement of any kind. |
|
|